Disclosure of voting rights for Chairman of the Board

Posted on May 28, 2018

Oslo, 28 May 2018. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 29 May 2018. Mr. Bøhn holds 83,556 shares, representing 0.3 per cent […]

PCI Biotech initiates research collaboration with IMV Inc

Posted on May 24, 2018

Exploring synergies between PCI and DPX technologies to further enhance the effect of novel oncologic therapies Oslo (Norway) 24 May 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that it is initiating a preclinical research collaboration with IMV Inc (TSE:IMV) (OTCQX:IMMVD) Nova Scotia (Canada), a clinical stage biopharmaceutical corporation focused […]

PCI Biotech to present at BioEquity Europe

Posted on May 15, 2018

Oslo, Norway, May 15, 2018 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the Company at BioEquity Europe, an investor and partnering event. The event is taking place at Het Pand, Ghent, Belgium, 15-16 May 2018. Mr. Ronny Skuggedal, CFO, will present an […]